Menu
Search
|

Menu

Close
X

Alnylam Pharmaceuticals Inc ALNY.OQ (NASDAQ Stock Exchange Global Select Market)

83.69 USD
+0.52 (+0.63%)
As of Sep 13
Previous Close 83.17
Open 83.14
Volume 394,997
3m Avg Volume 294,520
Today’s High 85.67
Today’s Low 83.04
52 Week High 99.62
52 Week Low 60.28
Shares Outstanding (mil) 110.98
Market Capitalization (mil) 8,393.51
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.94 Mean rating from 17 analysts

KEY STATS

Revenue (mm, USD)
FY19
33
FY18
75
FY17
90
FY16
47
EPS (USD)
FY19
-1.726
FY18
-7.573
FY17
-5.410
FY16
-4.791
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
97.26
7.90
Price to Book (MRQ)
vs sector
5.21
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
1.94
17.64
LT Debt to Equity (MRQ)
vs sector
1.94
12.61
Return on Investment (TTM)
vs sector
-43.69
12.69
Return on Equity (TTM)
vs sector
-48.59
17.13

EXECUTIVE LEADERSHIP

Michael Bonney
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Barry Greene
President, Since 2016
Salary: $580,000.00
Bonus: $232,000.00
John Maraganore
Chief Executive Officer, Director, Since 2007
Salary: $800,000.00
Bonus: $480,000.00
Manmeet Soni
Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: $500,000.00
Bonus: $160,000.00
Akshay Vaishnaw
President - Research and Development, Since 2018
Salary: $570,000.00
Bonus: $228,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 3rd St
CAMBRIDGE   MA   02142-1103

Phone: +1617.5518200

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

SPONSORED STORIES